Elsevier

Surgical Oncology

Volume 20, Issue 1, March 2011, Pages e38-e54
Surgical Oncology

Review
Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: State of the art and future developments

https://doi.org/10.1016/j.suronc.2010.09.002Get rights and content

Abstract

Peritoneal carcinomatosis (PC) had long been regarded as a terminal disease, characterized by a very poor survival and worth treating with palliative therapy. A new strategy combining maximal surgery (cytoreductive surgery, CRS), with maximal regional chemotherapy (hyperthermic intraperitoneal chemotherapy, HIPEC), has been proposed to treat PC, resulting in long-term survival rates in selected patients. The emerging trend is to view localised peritoneal carcinomatosis, in the absence of other metastases, as a regional metastatic disease that is amenable to locoregional therapy. In spite of the need for more high quality studies, many international experts now agree that the use of this new strategy is a gold standard for treating selected patients with PC with the intent of curing. The best results are achieved in patients with limited disease who have completed macroscopic tumor removal. To offer a comprehensive review, we summarized the present status and possible future progress of this treatment modality, in particular outlining its rationale, current practice and general outcome.

Introduction

Peritoneal carcinomatosis (PC) is a clinical entity with unfavourable prognosis that commonly characterises the terminal evolution of abdominopelvic neoplastic diseases [1]. Traditionally, this condition has been regarded as a lethal disease, as most patients with carcinomatosis die within 6 months [2], [3]. Being particularly difficult to treat, cancers with widespread peritoneal dissemination often cause their great morbidity and mortality through progressive involvement of the peritoneal surfaces. Even in patients resected for intra-abdominal carcinomas, PC is the most common cause of death [4], [5], [6]

During the last decade, there has been renewed interest in peritoneal-surface malignancy. The improved understanding of the biology of tumors with intraperitoneal dissemination without evidence of systemic metastases has prompted the search for new aggressive therapeutic approaches. Intraperitoneal chemohyperthermia in the first place, since 1980 [7], and successively combined with peritonectomy procedures, since 1995 [8], has been used for the treatment of PC deriving from gynecological and nongynecological malignancies. Since then, various cancer treatment centers all over the world have become interested in this treatment modality and have reported their experience with HIPEC using different devices with encouraging preliminary results [2]. Globally, as most synchronous PC is confined to the peritoneal cavity and is a localised disease [1], there is an evolving paradigm shift in the management of PC to achieve locoregional control, similar to hepatectomy for patients with isolated liver metastasis deriving from colorectal carcinoma.

This innovative and aggressive treatment regimen directed at the whole abdomen and pelvis is able, despite high post-operative morbidity rates, to eradicate carcinomatosis and improve long-term survival rates for selected patients [8], [9]. The rationale for HIPEC is based on direct cytotoxicity of hyperthermia against malignant cells, enhancement of the cytotoxicity of anticancer drugs, and the pharmacokinetic advantages of the intraperitoneal route for chemotherapy [4], [6].

The biological basis of PC and the most recent knowledge on this new treatment modality are here comprhensively reviewed. Future directions are conclusively discussed.

Section snippets

Epidemiology

Primary peritoneal malignant disorders (such as peritoneal mesothelioma) are rare, while PC is a common manifestation of digestive-tract and gynecological cancers, usually appendiceal tumours, ovarian cancer, colorectal cancer, or gastric cancer [2].

The peritoneal dissemination may be present at the time of diagnosis of the primary tumor, but it arises more frequently as a tumor recurrence after radical surgical treatment [4]. In gastric cancer, 10–20% of patients deputed for potentially

Pathophysiology of peritoneal carcinomatosis

The mechanisms governing carcinomatosis are multifactorial. Basically, they include the peritoneal dissemination of free cancer cells, exfoliating as a consequence of direct invasion by the primary tumor [23]. Subsequently, they implant to the peritoneal surface right through the presence of adhesion molecules [4], [5]. Another mechanism considered responsible of peritoneal dissemination is the passage of malignant cells through lymphatic fluid or venous blood, which are retained within the

History

Beginning from studies on ovarian cancer, in the 1930s Meigs was the first to advocate CRS followed by adjuvant radiotherapy [25] and, successively, the concept of ultraradical cytoreduction of PC was optimized in the late 1960s and 1970s, when Munnell and Griffiths independently demonstrated improved survival rates achieved by more extensive surgery with the size of residual disease being the most important prognostic factor [26], [27].

In 1969 Long et al. [28] reported long survival times in

Rationale

As shown by pharmacokinetic studies [4], [5], [6], when an antitumor drug was administered intraperitoneally in large volumes, a significantly greater concentration was obtained in the abdominal cavity compared with the circulating blood. Because the peritoneal permeability is considerably less than the plasma clearance, this ‘peritoneal plasma barrier’ mechanism provides locally dose-intensive therapy, so that higher concentrations of anticancer drugs can act in direct contact with tumor cells

Technique

A number of different techniques for the administration of intraperitoneal chemotherapy in hyperthermia associated with CRS have been described. Mainly variations in perfusate temperature, chemotherapeutic drug and dosage, total volume of instillate, duration of intraperitoneal chemotherapy, temperature of dynamic flow, and whether the abdomen remain open or not during the perfusion have been reported [2].

Indications

The common conditions of peritoneal diseases to be treated with this procedure are those limited to the abdomen that is completely or significantly resectable. These usually originated from gastric cancer, colorectal cancer, appendiceal cancer, and ovarian cancer. Also primary peritoneal malignancies are candidate.

However, qualitative and quantitative indicators are needed to assess patient’s eligibility for such an invasive form of treatment. Patients must be able to medically and safely

Prognostic indicators

Quantitative prognostic indicators are generally useful to guide selection of patients who are most likely to respond to the treatment and to exclude those who have little or no chance of benefiting from this high-risk management protocols. Unfortunately, to date, firmly codified indicators for the selection of patients for cytoreduction plus HIPEC are not available.

Preoperative imaging, essentially TC and MRI, that theoretically could assist not only in planning cytoreduction but also in

Morbidity and mortality

Such procedures are generally long and technically challenging, and it is not surprising that considerable rates of morbidity and mortality may result, particularly when HIPEC is combined with extensive cytoreduction [16], [35], [36], [39].

Despite having been in existence for about 20 years, there still exists a lack of acceptance of this treatment, essentially due to the high morbidity and mortality that for long has been regarded as the main cause of criticism against the safety of this

Survival

Systemic chemotherapy demonstrates little impact on the treatment of peritoneal malignancy. Despite showing encouraging tumor response rates, it does not definitively improve survival rates [2].

To date, no prospective randomized study has been conducted to evaluate the efficacy of cytoreduction plus HIPEC for the treatment of PC regardless of primary-tumor type; whereas, a single randomized controlled study specifically designed for the treatment of PC of colorectal cancer origin [82] is

State of the art and future prospects

The operative procedures, CRS, and the HIPEC systems are expensive and complex in design and application for the particular aggressive treatment modality needed for carcinomatosis. They require not only highly specialized human resources, but also complex technological facilities, for which a learning curve exists too. Over the years numerous groups of surgeons have become involved, but at present only few centers have gained experience exceeding 100 cases and HIPEC procedure has not been

Conclusion

Cytoreductive surgery and HIPEC are an aggressive multidisciplinary approach to a difficult oncologic situation which demonstrates a positive emerging trend towards the expected survival rates in patients with PC.

On the basis of published evidence, HIPEC impacts on the survival rate after complete CRS, thus a potential cure of PC is at present a realistic option that can no longer be ignored. Nevertheless, it is clear that CRS plus HIPEC is not indicated for all patients with PC, but has an

Conflict of interest statement

All the authors disclose any potential or actual personal, political or financial interest in the material, information or techniques described in the paper.

Authorship Statement

Guarantor of the integrity of the study: Enrico Pinto

Study concepts:Franco Roviello

Study design: Stefano Caruso, Alfonso De Stefano

Definition of intellectual content: Daniele Marrelli

Literature research: Alessandro Neri, Corrado Pedrazzani

Clinical studies:Bin Wu, Xuefeng Liu, Guiyang Cai

Acknowledgements

All authors disclose any potential or actual personal, political or financial conflict of interest in the material, information or techniques described in the paper.

References (111)

  • J. Hagendoorn et al.

    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival

    Eur J Surg Oncol

    (2009)
  • K.S. Ryu et al.

    Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer

    Gynecol Oncol

    (2004)
  • C. Omohwo et al.

    Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology

    J Am Coll Surg

    (2009)
  • S. Gonzalez-Moreno

    Peritoneal surface oncology: a progress report

    Eur J Surg Oncol

    (2006)
  • H.A. Al-Shammaa et al.

    Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis

    World J Gastroenterol

    (2008)
  • T.C. Chua et al.

    Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality

    Ann Surg

    (2009)
  • P.H. Sugarbaker

    Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis

    Semin Surg Oncol

    (1998)
  • P.H. Sugarbaker

    Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology

    Peritoneal carcinomatosis: principles and management

    (1996)
  • K. Van der Speeten et al.

    Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy

    Cancer J

    (2009)
  • J.S. Spratt et al.

    Clinical delivery system for intraperitoneal hyperthermic chemotherapy

    Cancer Res

    (1980)
  • P.H. Sugarbaker

    Peritonectomy procedures

    Ann Surg

    (1995)
  • J. Esquivel et al.

    Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients

    Ann Surg

    (2001)
  • Y. Kodera et al.

    Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection

    J Surg Oncol

    (1999)
  • F. Roviello et al.

    Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity

    World J Surg

    (2006)
  • S. Fujimoto et al.

    Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma

    Cancer

    (1999)
  • D. Marrelli et al.

    Italian research group for gastric cancer; Italian research group for gastric cancer. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study

    World J Surg

    (2002)
  • F. Roviello et al.

    Italian research group for gastric cancer; Italian research group for gastric cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer

    Br J Surg

    (2003)
  • A.G. Portilla et al.

    Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update

    Rev Esp Enferm Dig

    (2005)
  • B. Sadeghi et al.

    Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study

    Cancer

    (2000)
  • T.C. Chua et al.

    Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results

    J Cancer Res Clin Oncol

    (2009)
  • B. Moran et al.

    Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei)

    J Surg Oncol

    (2008)
  • J. Esquivel et al.

    Society of Surgical Oncology Annual Meeting. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology

    Ann Surg Oncol

    (2007)
  • M. Deraco et al.

    Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion

    Ann Surg Oncol

    (2006)
  • J.H. Stewart et al.

    Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions

    Ann Surg Oncol

    (2005)
  • Y. Yonemura et al.

    Mechanisms of formation of peritoneal dissemination

    Peritoneal dissemination – molecular mechanisms and the latest therapy

    (1998)
  • J.V. Meigs

    Tumors of the female pelvic organs

    (1934)
  • C.T. Griffiths et al.

    Role of cytoreductive surgical treatment in the management of advanced ovarian cancer

    Cancer Treat Rep

    (1979)
  • W.P. Ceelen et al.

    Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer

    Br J Surg

    (2000)
  • J.M. Larkin et al.

    Systemic thermotherapy. Description of a method and physiologic tolerance in clinical subjects

    Cancer (Phila.)

    (1977)
  • W.W. Shingleton et al.

    Abdominal perfusion for cancer chemotherapy with hypothermia and hyperthermia

    Surgery

    (1961)
  • Palta JR. Design and testing of a therapeutic infusion filtration system, M.S. thesis. University of Missouri,...
  • J.S. Spratt et al.

    Hyperthermic peritoneal perfusion system in canines

    Cancer Res

    (1980)
  • P.H. Sugarbaker

    Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment

    Langenbecks Arch Chir

    (1988)
  • S. Koga et al.

    Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with anticancer drugs

    Cancer Res

    (1984)
  • S. Fujimoto et al.

    Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seedings

    Ann Surg

    (1988)
  • F.N. Gilly et al.

    Intraperitoneal chemohyperthermia with mitomycin C in dogs: general, biological and anastomotic tolerance

    Int J Hyperthermia

    (1992)
  • F.N. Gilly et al.

    Regional chemotherapy with mitomycin C and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis

    Hepatogastroenterology

    (1994)
  • A.C. Beaujard et al.

    Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis

    Cancer

    (2000)
  • M.F. Flessner

    The transport barrier in intraperitoneal therapy

    Am J Physiol Ren Physiol

    (2005)
  • E.P. Armour et al.

    Sensitivity of human cells to mild hyperthermia

    Cancer Res

    (1993)
  • Cited by (88)

    View all citing articles on Scopus
    View full text